 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...3839404142434445464748...858859» |
- || Repatha (evolocumab) / Amgen, Astellas
Trial initiation date: Mechanistic Clinical Trial of PCSK9 Inhibition for AAA (clinicaltrials.gov) - Aug 20, 2024
P1, N=44, Not yet recruiting, Sponsor: University of Pennsylvania
Initiation date: Jul 2024 --> Dec 2024
- ganitumab (AMG 479) / Takeda, ImmunityBio
Phase classification, Combination therapy, Metastases: QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors (clinicaltrials.gov) - Aug 20, 2024
P1/2, N=89, Terminated, Sponsor: NantCell, Inc.
Initiation date: Jul 2024 --> Dec 2024 Phase classification: P1b/2 --> P1/2
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion date, Trial primary completion date, Combination therapy: Off-the-shelf NK Cells + SCT for Myeloid Malignancies (clinicaltrials.gov) - Aug 19, 2024
P1/2, N=24, Recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P1b/2 --> P1/2 Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 19, 2024
P3, N=6720, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026 Suspended --> Active, not recruiting
- | Stivarga (regorafenib) / Bayer
Biomarker, Journal, Checkpoint inhibition, IO biomarker, Metastases: Clinical predictive factors of the efficacy of immune checkpoint inhibitors and kinase inhibitors in advanced hepatocellular cancer. (Pubmed Central) - Aug 19, 2024
PLR and TC were potential clinical predictive factors for survival outcomes in patients with advanced HCC who received ICI/kinase inhibitor combination therapy. It is important to know the clinical characteristics of patients prior to treatment initiation to optimize outcomes.
- || Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Review, Journal: Use of biologic therapies in the management of pyoderma gangrenosum: a systematic review. (Pubmed Central) - Aug 19, 2024
PG recurred in 15.5% (11/71) of those reported the outcome. Our study suggests that biologic therapies may be an attractive therapeutic option for PG with an excellent efficacy.
- || Granocyte (lenograstim) / Roche, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Review, Journal: Forty years of human G-CSF: A short history in time. (Pubmed Central) - Aug 19, 2024
In 1987, clinical trials began using recombinant G-CSF in cancer patients following chemotherapy to reduce the duration of neutropenia and in patients with congenital neutropenia (CN) to increase the number of neutrophils. It has changed the quality of life for many cancer patients and saved the lives of many patients with (CN).
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal: Effective treatment of relapsed/refractory CD19-positive B/T-type mixed-phenotype acute leukemia with blinatumomab: A case report. (Pubmed Central) - Aug 19, 2024
He was next administered blinatumomab with dexamethasone pretreatment, resulting in a complete remission (CR)...He has still maintained a CR for 12 months. Blinatumomab might be a promising treatment and a bridge to stem cell transplantation even in relapsed/refractory CD19-expressing MPAL-B/T.
- | Prolia (denosumab) / Amgen
Journal, Real-world evidence, Real-world: Incidence and prevention of skeletal-related events in multiple myeloma patients: A population-based real-world experience. (Pubmed Central) - Aug 19, 2024
SREs are still a common problem in an era of novel treatment. Cumulative dosage of BPs was lower than recommended, and treatment with BPs was safe in this population.
- | Repatha (evolocumab) / Amgen, Astellas
Journal: Use of Evolocumab in Familial (Pubmed Central) - Aug 19, 2024
Cumulative dosage of BPs was lower than recommended, and treatment with BPs was safe in this population. We describe a novel use of evolocumab for successful postoperative lipid control in a patient with familial hyperlipidemia
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Impact of Erenumab on Migraine Disability: A Three-Month MIDAS (Migraine Disability Assessment Scale) Score Analysis at Dubai Health Facilities. (Pubmed Central) - Aug 19, 2024
While not statistically significant due to the limited sample size and the absence of a control group, these findings suggest a potential benefit of erenumab in reducing migraine disability. Future research with more extensive, controlled trials is warranted to definitively assess erenumab's effectiveness and explore potential treatment regimen variations for optimal patient outcomes.
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial completion date: CheckMate 9N9: An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (clinicaltrials.gov) - Aug 19, 2024
P1/2, N=325, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Future research with more extensive, controlled trials is warranted to definitively assess erenumab's effectiveness and explore potential treatment regimen variations for optimal patient outcomes. N=232 --> 325 | Trial completion date: Mar 2024 --> Oct 2024
- | dexrazoxane / Generic mfg.
Enrollment open: HO170DLBCL: Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma (clinicaltrials.gov) - Aug 19, 2024
P3, N=324, Recruiting, Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
N=232 --> 325 | Trial completion date: Mar 2024 --> Oct 2024 Not yet recruiting --> Recruiting
- | zetomipzomib (KZR-616) / Kezar
Enrollment closed: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) (clinicaltrials.gov) - Aug 19, 2024
P2, N=24, Active, not recruiting, Sponsor: Kezar Life Sciences, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Scemblix (asciminib) / Novartis
Enrollment open: Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 19, 2024
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date, Trial initiation date, Trial primary completion date: Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg (clinicaltrials.gov) - Aug 19, 2024
P4, N=24, Completed, Sponsor: Megalabs
Not yet recruiting --> Recruiting Not yet recruiting --> Completed | Trial completion date: Aug 2024 --> May 2024 | Initiation date: May 2024 --> Feb 2024 | Trial primary completion date: Aug 2024 --> Apr 2024
- ||||| lisaftoclax (APG-2575) / Ascentage Pharma
Trial suspension, Combination therapy, Metastases: A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer (clinicaltrials.gov) - Aug 19, 2024
P1/2, N=65, Suspended, Sponsor: Ascentage Pharma Group Inc.
Not yet recruiting --> Completed | Trial completion date: Aug 2024 --> May 2024 | Initiation date: May 2024 --> Feb 2024 | Trial primary completion date: Aug 2024 --> Apr 2024 Recruiting --> Suspended
- ||||| Epogen (epoetin alfa) / Amgen
Trial initiation date: ENCASE: Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients (clinicaltrials.gov) - Aug 18, 2024
P3, N=280, Not yet recruiting, Sponsor: Megalabs
Recruiting --> Suspended Initiation date: Jul 2024 --> Jul 2025
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 18, 2024
P3, N=6720, Suspended, Sponsor: National Cancer Institute (NCI)
Initiation date: Jul 2024 --> Jul 2025 Trial completion date: Jun 2029 --> Sep 2027 | Trial primary completion date: Jun 2029 --> Sep 2027
- | Stivarga (regorafenib) / Bayer
New P2 trial, Combination therapy, Checkpoint inhibition, IO biomarker, Metastases: GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. (clinicaltrials.gov) - Aug 18, 2024
P2, N=120, Not yet recruiting, Sponsor: Chinese PLA General Hospital
- | Enbrel (etanercept) / Pfizer, Amgen
Journal: Multimodal Imaging of Structural Damage and Inflammation in Psoriatic Arthritis: A comparison of DMARD-Naive and DMARD-Failure Patients. (Pubmed Central) - Aug 17, 2024
P4
At baseline, PsA patient groups were comparable concerning structural and inflammatory imaging parameters, especially after correcting for patient characteristics. Thus, DMARD-naive and DMARD-failure patient groups may be combined in future PsA progression and treatment decision studies.
- || Clinical, Journal: Drug Survival on First Biologic Therapy Among Late-Onset Rheumatoid Arthritis Patients Compared to Early-Onset Patients: A Population-Based Cohort Study. (Pubmed Central) - Aug 17, 2024
Thus, DMARD-naive and DMARD-failure patient groups may be combined in future PsA progression and treatment decision studies. Late-onset RA patients were treated with biologics to a lesser extent than early-onset patients, but no differences were observed in drug survival times at the first bDMARD between the two groups.
- || Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Clinical, Retrospective data, Journal, HEOR, Real-world evidence, Real-world, Metastases: Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR?+?/HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand. (Pubmed Central) - Aug 17, 2024
No statistically significant difference in PFS, OS, and TTC was found in patients treated with AI combined with palbociclib or ribociclib. Longer follow-up and further prospective randomized head-to-head studies are warranted.
- || Ibrance (palbociclib) / Pfizer, Votrient (pazopanib) / Novartis
Review, Journal: Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration. (Pubmed Central) - Aug 17, 2024
For these interactions, it is very important to use the precautionary principle and warn patients and physicians about this. In patients who require acid suppression because of severe symptoms, using antacids or H2 blockers could be recommended.
- | Journal: Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics. (Pubmed Central) - Aug 17, 2024
Current developments include testing of avatrombopag and lusutrombopag that are approved for the treatment of thrombocytopenia associated with chronic liver disease (CLD) in adult patients. In pediatric and adolescent medicine, we expect in the near future a broader use of TPO-RAs as first-line treatment in primary ITP, thereby considering immunomodulatory effects that increase the rate of sustained remission off-treatment, and a selective use in rare inherited thrombocytopenias based on current clinical trials.
- || Prolia (denosumab) / Amgen
Review, Journal: Denosumab as treatment of central giant cell granuloma of the jaws. a scoping review. (Pubmed Central) - Aug 17, 2024
Common ADRs were hypo and hypercalcemia. Further studies are needed to define dose and supplementation protocols to avoid ADRs during and after therapy.
- | Journal: Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases. (Pubmed Central) - Aug 17, 2024
Further studies are needed to define dose and supplementation protocols to avoid ADRs during and after therapy. In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.
- | Prolia (denosumab) / Amgen
Journal: Squamous cell carcinoma of mandibular gingiva producing both parathyroid hormone-related protein and granulocyte colony-stimulating factor: a case report. (Pubmed Central) - Aug 17, 2024
Based on these clinical and pathological findings, the patient was diagnosed with hypercalcaemia and leukocytosis associated with malignancy and was treated with denosumab...Therefore, chemotherapy was discontinued. One week after the chemotherapy was discontinued, the patient died of respiratory failure.
- || Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Review, Journal: Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients. (Pubmed Central) - Aug 16, 2024
Like B-ALL, the only existing approved therapy for relapsed T-ALL, nelarabine, is now used in the upfront treatment setting potentially limiting its utility in relapsed disease. Over the next several years, the hope is for patients diagnosed with T-ALL to experience the drastic improvement in outcomes as has been seen for patients diagnosed with B-ALL over the last decade.
- | Stivarga (regorafenib) / Bayer
Journal: The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma. (Pubmed Central) - Aug 16, 2024
Over the next several years, the hope is for patients diagnosed with T-ALL to experience the drastic improvement in outcomes as has been seen for patients diagnosed with B-ALL over the last decade. In this study, we explored whether regorafenib and RT exert a synergetic effect on the treatment of HCC.
- | Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Journal: Ferritin-based disruptor nanoparticles: A novel strategy to enhance LDL cholesterol clearance via multivalent inhibition of PCSK9-LDL receptor interaction. (Pubmed Central) - Aug 16, 2024
Our findings highlight the potential of ferritin-based platforms as versatile tools for targeting PCSK9 in the management of hypercholesterolemia. This study not only contributes to the advancement of ferritin-based therapeutics but also offers valuable insights into novel strategies for treating cardiovascular diseases.
- | erythromycin / Generic mfg., ivabradine / Generic mfg.
Journal: Generic mitigating and promoting effect of zeolite on anaerobic digestion: Physicochemical and metataxonomic data. (Pubmed Central) - Aug 16, 2024
The sequencing data were generated using the Ion Torrent PGM sequencer and have been deposited in the European Nucleotide Archive (ENA) database at EMBL-EBI under accession number PRJEB65129 (https://www.ebi.ac.uk/ena/browser/view/PRJEB65129), with sample accession numbers ranging from ERS16257742 to ERS16257691 [2]. The data serves as a valuable resource for comparisons with data from other studies on lab-scale batch anaerobic digesters, particularly those utilizing zeolite as a support material or involving inhibition caused by similar types of inhibitors (salts, antibiotics, or pesticides).
- ||| Praluent (alirocumab) / Sanofi, Regeneron, Henletor (torsemide) / Orchid, Repatha (evolocumab) / Amgen, Astellas
Journal, Adverse events: Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study. (Pubmed Central) - Aug 16, 2024
Through the FAERS database, we analyzed the clinical characteristics of AKI associated with PCSK9 inhibitors, exploring its risks. Our findings suggest that PCSK9 inhibitors might have a potential protective effect against AKI and exhibit similar effects when co-administered with other nephrotoxic drugs.
- | Ibrance (palbociclib) / Pfizer, Mekinist (trametinib) / Novartis, BeiGene
Journal: Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease models. (Pubmed Central) - Aug 16, 2024
The TBK1(TANK-binding kinase 1) inhibitor GSK8612 selectively blocked the induction of interferon-related genes induced by palbociclib and trametinib treatment, and highlighted the separable epigenetic responses elicited by combined CDK4/6 and MEK inhibition. Together, these findings provide key mechanistic insights into the therapeutic potential of CDK4/6 and MEK inhibition in soft tissue sarcoma.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P4 trial: CAT: Combined Anabolic Therapy (clinicaltrials.gov) - Aug 16, 2024
P4, N=46, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | Prolia (denosumab) / Amgen
Enrollment open: Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes (clinicaltrials.gov) - Aug 16, 2024
P3, N=86, Recruiting, Sponsor: Wuhan Union Hospital, China
Together, these findings provide key mechanistic insights into the therapeutic potential of CDK4/6 and MEK inhibition in soft tissue sarcoma. Not yet recruiting --> Recruiting
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion date, Trial primary completion date: A Study of Romosozumab in Women with Multiple Myeloma and Osteoporosis (clinicaltrials.gov) - Aug 15, 2024
P1, N=10, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
- || Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Current perspectives of KRAS in non-small cell lung cancer. (Pubmed Central) - Aug 15, 2024
To date, two G12C inhibitors have been FDA-approved, namely sotorasib and adagrasib. In this review, we summarize the different drug combinations used to target KRAS G12c, upcoming G12D inhibitors and novel therapies targeting KRAS.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
P3 data, Journal, Metastases: Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. (Pubmed Central) - Aug 15, 2024
P3
In patients with pMMR or not MSI-H mCRC that had progressed on previous therapy, there was no statistically significant improvement in OS after lenvatinib plus pembrolizumab treatment versus SOC. No new safety signals were observed.
- | Repatha (evolocumab) / Amgen, Astellas
Journal: A Temporal Association between Regression of Pachydrusen and Use of Proprotein Convertase Subtilisin Kexin 9 Inhibitor: A Case Report. (Pubmed Central) - Aug 15, 2024
Recurrence of drusen was observed after discontinuing the drug. Use of PCSK9 inhibitors may improve the retina's lipid homeostasis by increasing the number of RPE-LDL receptors and partly contribute to the improvement of ocular phenotypes associated with dysfunctional RPE in pachychoroidopathy.
- | Prolia (denosumab) / Amgen
Journal: Parathyroid Hormone-Related Protein-Producing Adenocarcinoma Suspicious of Lung Cancer: A Case Report. (Pubmed Central) - Aug 15, 2024
The serum calcium level was reduced by denosumab, but the patient died 20 days after admission. The present case demonstrated the importance of considering oncological emergency, such as hypercalcemia and/or PTH-rP-producing hypercalcemia, in patients with adenocarcinoma.
- || briquilimab (JSP191) / Jasper Therap
Trial primary completion date: BEACON: Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) (clinicaltrials.gov) - Aug 15, 2024
P1/2, N=52, Recruiting, Sponsor: Jasper Therapeutics, Inc.
The present case demonstrated the importance of considering oncological emergency, such as hypercalcemia and/or PTH-rP-producing hypercalcemia, in patients with adenocarcinoma. Trial primary completion date: Oct 2024 --> Oct 2025
- EFFICACY AND SAFETY OF PEGYLATED FILGRASTIM AS PRIMARY PROPHYLAXIS FOLLOWING PEDIATRIC DOSE-INTENSIVE CHEMOTHERAPY: A RANDOMIZED CONTROLLED TRIAL (315 Hall) - Aug 15, 2024 - Abstract #SIOP2024SIOP_589;
Duration of ANC recovery, depth of ANC nadir, and adverse events reported were not significantly different in both arms.Conclusions The incidence of FN in the peg-filgrastim arm was significantly lesser. No significant adverse events attributable to the peg-filgrastim were reported.
- Blincyto (blinatumomab) / Astellas, Amgen
"JUST REALLY HAPPY TO BE HOME": PARENT EXPEREINCES OF CAREGIVING FOR A CHILD WITH LEUKEMIA RECEIVING HOME-BASED BLINATUMOMAB (311 Hall) - Aug 15, 2024 - Abstract #SIOP2024SIOP_491;
Conclusions Parents can confidently manage home-based continuous infusion blinatumomab with anticipatory guidance and support. Related parent insights should be reflected in the principles that become the basis of future pediatric B-cell ALL clinical trials and care.
- Blincyto (blinatumomab) / Astellas, Amgen
COMBINING A RECOMBINANT ONCOLYTIC MEASLES VIRUS WITH A BISPECIFIC T CELL ENGAGER: MV-BLINA AS A NEW THERAPEUTIC APPROACH TO TREAT BCP-ALL (311 Hall) - Aug 15, 2024 - Abstract #SIOP2024SIOP_463;
Background and Aims The CD19xCD3 bispecific T cell engager (BiTE) blinatumomab is effective against B cell precursor acute lymphoblastic leukemia (BCP-ALL) by engaging CD3+ T cells with CD19+ leukemic blasts...Here, MV-Blina showed a pronounced oncolytic effect on the neuroblastoma cell line SY5Y while human iPSC-derived neurons were less affected. The toxicity of MV-Blina is being investigated in a susceptible mouse model.Conclusions Altogether, we showed cytotoxic efficacy of MV-Blina in BCP-ALL, warranting further clinical preclinical evaluation of this promising new therapeutic approach.
- | Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: DEPEND: De-Escalation Therapy for Human Papillomavirus Negative Disease (clinicaltrials.gov) - Aug 15, 2024
P2, N=36, Recruiting, Sponsor: University of Chicago
The toxicity of MV-Blina is being investigated in a susceptible mouse model.Conclusions Altogether, we showed cytotoxic efficacy of MV-Blina in BCP-ALL, warranting further clinical preclinical evaluation of this promising new therapeutic approach. Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- || xaluritamig (AMG 509) / Amgen
New P1 trial, Metastases: Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer (clinicaltrials.gov) - Aug 14, 2024
P1, N=40, Not yet recruiting, Sponsor: Amgen
- | Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
New P2 trial: Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL (clinicaltrials.gov) - Aug 14, 2024
P2, N=20, Recruiting, Sponsor: First Affiliated Hospital of Zhejiang University
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Role of sclerostin deletion in bisphosphonate-induced osteonecrosis of the jaw. (Pubmed Central) - Aug 14, 2024
Enhanced bone formation and wound healing were observed in the tooth extraction socket. The use of romosozumab (anti-sclerostin antibody) has proven to be safe for surgical procedures of the jaw.
- | Prolia (denosumab) / Amgen
Journal: The effect of preoperative embolization on giant cell tumors of the bone localized in the iliosacral region of the pelvis. (Pubmed Central) - Aug 14, 2024
Curettage of GCTB in the posterior pelvis and sacrum presents challenges, with significant intraoperative blood loss impacting surgical time and transfusion needs. Preoperative embolization may be beneficial in reducing blood loss during surgery in these cases.